Jinling Pharmaceutical Co Ltd Asset Resilience Ratio

Latest as of September 2025: 21.60%

Jinling Pharmaceutical Co Ltd asset resilience ratio. Jinling Pharmaceutical Co Ltd (000919) has an Asset Resilience Ratio of 21.60% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 000919 days of operational coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥1.30 Billion
≈ $190.40 Million USD Cash + Short-term Investments

Total Assets

CN¥6.02 Billion
≈ $881.50 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of Jinling Pharmaceutical Co Ltd (1999–2024)

Asset resilience ratio of Jinling Pharmaceutical Co Ltd from 1999 to 2024. This chart shows how Jinling Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read how much debt does Jinling Pharmaceutical Co Ltd carry for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Jinling Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Jinling Pharmaceutical Co Ltd asset portfolio.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥1.30 Billion 21.6%
Total Liquid Assets CN¥1.30 Billion 21.60%

Asset Resilience Insights

  • Good Liquidity Position: Jinling Pharmaceutical Co Ltd maintains a healthy 21.60% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Jinling Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jinling Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Sandoz Group AG
SW:SDZ
Drug Manufacturers - Specialty & Generic 7.89%
H Lundbeck A/S
CO:HLUN-B
Drug Manufacturers - Specialty & Generic -0.56%
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 5.50%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 47.16%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%
Viyash Scientific Limited
NSE:SEQUENT
Drug Manufacturers - Specialty & Generic 0.08%
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
Drug Manufacturers - Specialty & Generic 1.81%

Jinling Pharmaceutical Co Ltd Asset Resilience Ratio by Year (1999–2024)

Jinling Pharmaceutical Co Ltd asset resilience ratio by year from 1999 to 2024. The table below shows the annual Asset Resilience Ratio data for Jinling Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 11.60% CN¥706.05 Million
≈ $103.32 Million
CN¥6.09 Billion
≈ $890.99 Million
+9.78pp
2023-12-31 1.81% CN¥82.57 Million
≈ $12.08 Million
CN¥4.55 Billion
≈ $665.88 Million
-0.22pp
2022-12-31 2.03% CN¥92.35 Million
≈ $13.51 Million
CN¥4.54 Billion
≈ $664.84 Million
+2.00pp
2021-12-31 0.03% CN¥1.25 Million
≈ $183.06K
CN¥4.45 Billion
≈ $650.83 Million
0.00pp
2020-12-31 0.03% CN¥1.38 Million
≈ $201.35K
CN¥4.28 Billion
≈ $626.82 Million
-2.62pp
2019-12-31 2.65% CN¥110.28 Million
≈ $16.14 Million
CN¥4.16 Billion
≈ $608.50 Million
+1.30pp
2018-12-31 1.35% CN¥52.45 Million
≈ $7.67 Million
CN¥3.88 Billion
≈ $568.49 Million
-0.38pp
2017-12-31 1.73% CN¥66.76 Million
≈ $9.77 Million
CN¥3.86 Billion
≈ $564.40 Million
+0.66pp
2016-12-31 1.08% CN¥41.50 Million
≈ $6.07 Million
CN¥3.86 Billion
≈ $564.53 Million
-2.28pp
2015-12-31 3.36% CN¥129.18 Million
≈ $18.90 Million
CN¥3.85 Billion
≈ $563.41 Million
-1.52pp
2014-12-31 4.87% CN¥176.55 Million
≈ $25.83 Million
CN¥3.62 Billion
≈ $530.04 Million
+2.21pp
2013-12-31 2.66% CN¥87.97 Million
≈ $12.87 Million
CN¥3.30 Billion
≈ $483.54 Million
+1.74pp
2012-12-31 0.93% CN¥29.61 Million
≈ $4.33 Million
CN¥3.20 Billion
≈ $468.10 Million
-4.40pp
2011-12-31 5.33% CN¥157.59 Million
≈ $23.06 Million
CN¥2.96 Billion
≈ $432.89 Million
-1.70pp
2010-12-31 7.02% CN¥192.70 Million
≈ $28.20 Million
CN¥2.74 Billion
≈ $401.50 Million
-1.03pp
2009-12-31 8.05% CN¥197.68 Million
≈ $28.93 Million
CN¥2.46 Billion
≈ $359.32 Million
+3.66pp
2008-12-31 4.39% CN¥96.78 Million
≈ $14.16 Million
CN¥2.20 Billion
≈ $322.34 Million
-7.92pp
2007-12-31 12.31% CN¥291.34 Million
≈ $42.63 Million
CN¥2.37 Billion
≈ $346.26 Million
+5.66pp
2006-12-31 6.65% CN¥134.90 Million
≈ $19.74 Million
CN¥2.03 Billion
≈ $296.92 Million
+0.87pp
2005-12-31 5.78% CN¥106.44 Million
≈ $15.58 Million
CN¥1.84 Billion
≈ $269.67 Million
-2.63pp
2004-12-31 8.40% CN¥150.59 Million
≈ $22.04 Million
CN¥1.79 Billion
≈ $262.23 Million
-0.07pp
2003-12-31 8.48% CN¥138.64 Million
≈ $20.29 Million
CN¥1.64 Billion
≈ $239.28 Million
-3.30pp
2002-12-31 11.78% CN¥181.15 Million
≈ $26.51 Million
CN¥1.54 Billion
≈ $225.01 Million
-0.64pp
2001-12-31 12.42% CN¥175.89 Million
≈ $25.74 Million
CN¥1.42 Billion
≈ $207.25 Million
-15.10pp
2000-12-31 27.52% CN¥336.29 Million
≈ $49.21 Million
CN¥1.22 Billion
≈ $178.84 Million
+10.39pp
1999-12-31 17.13% CN¥200.60 Million
≈ $29.35 Million
CN¥1.17 Billion
≈ $171.39 Million
--
pp = percentage points

About Jinling Pharmaceutical Co Ltd

SHE:000919 China Drug Manufacturers - Specialty & Generic
Market Cap
$607.02 Million
CN¥4.15 Billion CNY
Market Cap Rank
#10952 Global
#2968 in China
Share Price
CN¥6.67
Change (1 day)
+10.07%
52-Week Range
CN¥5.78 - CN¥8.91
All Time High
CN¥16.21
About

Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China and internationally. The company offers Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, multiple arteriosclerosis, phlebitis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, an… Read more